Honnorat J, Aguera M, Zalc B, Goujet C, Quach T, Antoine J C, Belin M F
INSERM Unité 433, Hôpital Neurologique, Lyon, France.
J Neuropathol Exp Neurol. 1998 Apr;57(4):311-22. doi: 10.1097/00005072-199804000-00002.
Paraneoplastic neurological diseases are disorders of the central nervous system, associated with neuronal degeneration in patients with systemic cancer, but are not a direct result of the tumor mass or metastasis. The biological diagnosis of these syndromes is based mainly on the detection, in the patient's serum and cerebrospinal fluid, of autoantibodies (anti-Hu, anti-Yo, for example), suggesting an autoimmune origin for these disorders. Recently, we described novel autoantibodies (anti-CV2 autoantibodies) associated with paraneoplastic neurological disease, which recognize a 66 kDa brain protein. We named this antigen POP66, for Paraneoplastic Oligodendrocyte Protein of 66 kDa molecular weight, as in the adult human, rat, and mouse brain, it is specifically expressed by a subpopulation of oligodendrocytes. This cell type specificity was surprising given the fact that the cell loss in the brains of patients with anti-CV2 autoantibodies is neuronal. POP66-expressing oligodendrocytes are distributed along the longitudinal axis of the brain according to an increasing rostro-caudal gradient, with no positive oligodendrocytes being found in the forebrain and the greatest number found in the spinal cord. In addition, in transverse sections of the spinal cord, the distribution of POP66-positive oligodendrocytes follows an increasing dorsal-to-ventral gradient, which may be related to different oligodendrocyte precursor pools. In addition, the neuronal loss without demyelination seen in the brains of patients with anti-CV2 autoantibodies, together with the exclusive oligodendroglial expression of POP66 in the adult brain, raises the question of the possible involvement of POP66 in neuron survival via neuron/oligodendrocyte interactions.
副肿瘤性神经系统疾病是中枢神经系统的疾病,与全身性癌症患者的神经元变性有关,但不是肿瘤块或转移的直接结果。这些综合征的生物学诊断主要基于在患者血清和脑脊液中检测到自身抗体(例如抗Hu、抗Yo),提示这些疾病的自身免疫起源。最近,我们描述了与副肿瘤性神经系统疾病相关的新型自身抗体(抗CV2自身抗体),它识别一种66 kDa的脑蛋白。我们将这种抗原命名为POP66,即分子量为66 kDa的副肿瘤性少突胶质细胞蛋白,因为在成年人类、大鼠和小鼠大脑中,它由少突胶质细胞的一个亚群特异性表达。考虑到抗CV2自身抗体患者大脑中的细胞损失是神经元性的,这种细胞类型特异性令人惊讶。表达POP66的少突胶质细胞沿大脑纵轴按前后梯度增加分布,前脑中未发现阳性少突胶质细胞,脊髓中数量最多。此外,在脊髓横切面上,POP66阳性少突胶质细胞的分布沿背腹梯度增加,这可能与不同的少突胶质细胞前体细胞池有关。此外,抗CV2自身抗体患者大脑中出现的无脱髓鞘的神经元损失,以及POP66在成人大脑中仅由少突胶质细胞表达,引发了POP66可能通过神经元/少突胶质细胞相互作用参与神经元存活的问题。